ABSTRACT
Antecedentes y objetivo: Los ensayos pivotales de omalizumab en urticaria crónica espontánea (UCE) tienen un periodo de tratamiento de entre 12 y 24 semanas. Sin embargo, muchos pacientes en práctica clínica requieren periodos de tratamiento más prolongados. Por ello el objetivo es presentar un algoritmo de manejo del fármaco. Materiales y métodos: El documento de consenso que detallamos nace de la puesta en común, aceptación, revisión y confrontación de la literatura reciente del grupo de trabajo de UCE "Xarxa d'Urticària Catalana i Balear" (XUrCB). Resultados: Se inicia el tratamiento a dosis autorizada y se ajusta la dosis en intervalos trimestrales en función del Urticaria Activity Score de los últimos 7 días (UAS7) y/o el Urticarial Control Test (UCT). Conclusiones: El algoritmo propuesto pretende servir de guía respecto a cómo ajustar dosis, cómo y cuándo parar el fármaco y el modo de reintroducirlo en casos de recaída
Background and objective: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. Material and methods: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. Results: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7 days, the Urticaria Control Test, or both. Conclusions: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse
Subject(s)
Humans , Urticaria/drug therapy , Omalizumab/administration & dosage , Algorithms , Consensus , Dosage/methods , Histamine H1 Antagonists/administration & dosage , Dose-Response Relationship, DrugABSTRACT
BACKGROUND AND OBJECTIVE: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. MATERIAL AND METHODS: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. RESULTS: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7days, the Urticaria Control Test, or both. CONCLUSIONS: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse.
Subject(s)
Algorithms , Anti-Allergic Agents/therapeutic use , Omalizumab/therapeutic use , Urticaria/drug therapy , Anti-Allergic Agents/administration & dosage , Chronic Disease , Humans , Omalizumab/administration & dosageABSTRACT
La sarcoidosis es una enfermedad crónica multisistémica de etiología desconocida. La histiocitosis eruptiva generalizada (HEG) es una forma rara de histiocitosis no Langerhans, de curso benigno y autorresolutivo. Presentamos el caso de una niña de 8 años de edad con sarcoidosis que fue inicialmente diagnosticada en forma errónea de HEG. Fue tratada con corticoides orales, metotrexato y adalimumab, con los que se logró un control insuficiente de la uveítis. La introducción de infliximab permitió un control del compromiso oftalmológico y reducir la dosis de corticoides. En algunos casos de sarcoidosis la falta de granulomas bien organizados en el inicio de la enfermedad, así como la presencia de células gigantes, puede sugerir diagnósticos alternativos como la histiocitosis no Langerhans. Aunque la experiencia del uso de antagonistas del factor de necrosis tumoral alfa en niños con sarcoidosis es limitada, puede ser útil en aquellos pacientes con enfermedad severa y refractaria(AU)
Sarcoidosis is a chronic multisystemic granulomatous disease of unknown origin. Generalised eruptive histiocytosis is a rare, benign, self-healing, non-Langerhans cell histiocytosis (non-LCH).We report the case of an 8-year-old girl with sarcoidosis who was misdiagnosed as non-LCH. She was treated with oral corticosteroids, methotrexate and adalimumab, but there was insufficient control of ocular disease. The introduction of infliximab achieved a control of the uveitis and enabled the corticosteroid dose to be tapered. In some cases of sarcoidosis the lack of well-organised granuloma formation at the beginning of the disease, and the presence of prominent giant cells may suggest alternative diagnoses, such as non-LCH. Although the experience of tumour necrosis factor-alpha antagonists use in children with sarcoidosis is limited, these drugs may be helpful for those patients experiencing a severe and refractory disease(AU)
Subject(s)
Humans , Female , Child , Sarcoidosis/diagnosis , Histiocytosis, Non-Langerhans-Cell/diagnosis , Diagnosis, Differential , Uveitis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
Sarcoidosis is a chronic multisystemic granulomatous disease of unknown origin. Generalised eruptive histiocytosis is a rare, benign, self-healing, non-Langerhans' cell histiocytosis (non-LCH). We report the case of an 8-year-old girl with sarcoidosis who was misdiagnosed as non-LCH. She was treated with oral corticosteroids, methotrexate and adalimumab, but there was insufficient control of ocular disease. The introduction of infliximab achieved a control of the uveitis and enabled the corticosteroid dose to be tapered. In some cases of sarcoidosis the lack of well-organised granuloma formation at the beginning of the disease, and the presence of prominent giant cells may suggest alternative diagnoses, such as non-LCH. Although the experience of tumour necrosis factor-α antagonists use in children with sarcoidosis is limited, these drugs may be helpful for those patients experiencing a severe and refractory disease.
